Exploratory Clinical Trials of Novel Interventions for Mental Disorders (R61/R33)
The purpose of this Funding Opportunity Announcement (FOA) is to support the efficient pilot testing of novel interventions for mental disorders in adults and children through an experimental therapeutics approach. Under this FOA, trials must be designed so that results, whether positive or negative, will provide information of high scientific utility and will support go/no-go decisions about further development or testing of the intervention. Studies of novel interventions include, but are not limited to behavioral, pharmacological, biologics-based, cognitive, device-based, interpersonal, physiological, or combined approaches. Support will be provided for up to two years (R61 phase) for preliminary milestone-driven testing of the interventions engagement of the therapeutic target, possibly followed by up to 3 years of support (R33 phase) for studies to replicate target engagement and relate change in the intervention target to functional or clinical effects. Ultimately, this R61/R33 FOA is intended to speed the translation of emerging basic science findings of mechanisms and processes underlying mental disorders into novel interventions that can be efficiently tested for their promise in restoring function and reducing symptoms for those living with mental disorders.
Office: National Institutes of Health
FBOWebmaster@OD.NIH.GOV
